Novel antidiabetic furostanolic saponin rich (fsr) fraction from fenugreek seeds
OwnerPawan Kumar Goelinventor
Life of this patent
Estimating the term…
Abstract
The present invention discloses a novel anti-diabetic composition extracted from fenugreek seeds. The same comprises a furostanolic-saponin-rich fraction (>70%) with approximately 30% protodioscin as one of the bioactive components. Pre-clinical studies in rats indicated significant glucose lowering effect of the fraction (31.5%) as compared to control after two weeks of oral treatment. Clinical studies in human volunteers indicated suitability of a dosage form of 500 mg given once or twice daily as anti-diabetic agent either alone or in combination with standard, synthetic anti-diabetic drugs such as metformin and glipizide in controlling plasma glucose levels.
Claims10
A novel, anti-diabetic fraction isolated from fenugreek seeds wherein the same comprises furostanolic saponins (>70%) isolated by a low-temperature process carried out below 80 degree Celsius and comprising the steps of:
- Primary extraction using lower aliphatic alcohols
- Ion-exchange chromatography using a mixed bed resin
- Secondary extraction using novel composite extraction solvent
The novel anti-diabetic furostanolic-saponin-rich fraction (>70%) which includes approximately 30% protodioscin as the major fraction, described substantially herein with reference to the detailed description.
Dependencies are inferred from the claim text.